(Q54111946)

24 May 2018

review article

1 reference

title

Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. (English)

1 reference

24 May 2018

1 reference

1 reference

Reed E

1

1 reference

24 May 2018

publication date

1 October 1998

1 reference

24 May 2018

published in

Cancer Treatment Reviews

1 reference

24 May 2018

volume

24

1 reference

24 May 2018

issue

5

1 reference

24 May 2018

page(s)

331-344

1 reference

24 May 2018

Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

The measurement of cisplatin-DNA adduct levels in testicular cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Interindividual human variation in cisplatinum sensitivity, predictable in an in vitro assay?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Molecular characterization of the human excision repair gene ERCC-1: cDNA cloning and amino acid homology with the yeast DNA repair gene RAD10.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Mechanisms of DNA excision repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Reconstitution of human DNA repair excision nuclease in a highly defined system

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Reaction mechanism of human DNA repair excision nuclease

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Enhanced XPA mRNA levels in cisplatin-resistant human ovarian cancer are not associated with XPA mutations or gene amplification.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

A preliminary risk-benefit assessment of paclitaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Sequences of taxol and cisplatin: a phase I and pharmacologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Formation of covalent complexes between human O6-alkylguanine-DNA alkyltransferase and BCNU-treated defined length synthetic oligodeoxynucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

The base excision repair pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Second pathway for completion of human DNA base excision-repair: reconstitution with purified proteins and requirement for DNase IV (FEN1).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

1 reference

7 January 2021

Where transcription meets repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Proliferating cell nuclear antigen is required for DNA excision repair

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Partial characterization of the DNA repair protein complex, containing the ERCC1, ERCC4, ERCC11 and XPF correcting activities

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Genomic characterization of the human DNA excision repair gene ERCC-1

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Expression of excision repair genes in non-malignant bone marrow from cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Stimulation of repair replication by 3-aminobenzamide in human fibroblasts with ligase I deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Loss of heterozygosity in human ovarian cancer on chromosome 19q.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Appropriate Partners Make Good Matches

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Mismatch repair, genetic stability, and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Isolation of an hMSH2-p160 Heterodimer That Restores DNA Mismatch Repair to Tumor Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Cisplatin and adriamycin resistance are associated with MutLalpha and mismatch repair deficiency in an ovarian tumor cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

p53 tumor-suppressor gene: clues to molecular carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

P53, cell cycle control and apoptosis: Implications for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Glutathione and drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

ERCC6, a member of a subfamily of putative helicases, is involved in Cockayne's syndrome and preferential repair of active genes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2898%2990056-1

7 January 2021

10.1016/S0305-7372(98)90056-1

Identifiers

DOI

1 reference

24 May 2018

1 reference

24 May 2018